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1 |  CASE PRESENTATION
1.1 | Case history
A three‐year‐old male Münsterländer dog was presented 
to the Lorrainevet ophthalmology service to explore vision 
loss associated with anosmia. The dog had a large hunting 
activity, he had never travelled outside its region (Lorraine, 
France), and he was adequately vaccinated and dewormed. 
This acute loss of vision had started 30 days prior. During 
the prior examination, the dog was alert without other signs 
than loss of vision. Bilateral primary chorioretinitis was di-
agnosed at this time, and the vet diagnosis hypothesis was 
toxoplasmosis. No clinical improvement was observed with 
treatment based on prednisolone (Dermipred, Ceva Santé 
Animale) 1  mg/kg/d and clindamycin (Zodon, Ceva Santé 
Animale) 11 mg/kg/d.
1.2 | General clinical examination
During his first presentation to the ophthalmology ser-
vice, the animal was ambulatory, slightly lethargic, and 
the rest of the clinical examination were within normal 
limits.
1.3 | Ophthalmic examination
Cotton ball test and menace response were absent on the 
both eyes (OU). Direct and indirect pupillary light reflexes 
were absent OU. The dazzle reflex was present but slow and 
incomplete OU. Biomicroscopic examination (Kowa SL17 
slit lamp, Kowa) showed minor conjunctival hyperemia and 
complete mydriasis OU. Fundic examination with indirect 
binocular ophthalmoscopy (Heine Omega 500, Herrsching; 
Volk 2.2, Panretinal lens, Mentor) revealed an ill‐defined 
papilledema, vast subretinal granulomas associated with 
detachment of the retina, as well as numerous small retinal 
hemorrhages OU (Figure 1). The intraocular pressure (IOP) 
by rebound tonometry (Tonovet, Icare) was within normal 
limits (OD: 13 mm Hg, OS: 12 mm Hg).
A diagnosis of hemorrhagic exudative chorioretinitis with 
partial detachment of the retina and granuloma formation was 
established.
Received: 16 April 2019 | Revised: 31 August 2019 | Accepted: 4 September 2019
DOI: 10.1002/ccr3.2491  
C A S E  R E P O R T
Cryptococcosis with ocular and central nervous system 
involvement in a 3‐year‐old dog
Jean‐Baptiste Barbry1  |   Anne Sophie Poinsard1  |   Eymeric Gomes2 |   
Alexane Durand3 |   Olivier Balland1
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
1Lorrainevet, Ludres, France
2C.H.V. Frégis, Arcueil, France
3Division of Clinical 
Radiology, Department of Clinical 
Veterinary Medicine, Vetsuisse 
Faculty, University of Bern, Bern, 
Switzerland
Correspondence
Jean‐Baptiste Barbry, Lorrainevet, 127 rue 
Pierre Gilles de Gennes, Ludres 54710, 
France.
Email: Ophtalmologie@lorrainevet.fr
Abstract
To date, cryptococcosis remains sporadic in Europe, and this is a case of canine cryp-
tococcosis with ocular and CNS involvement in continental Europe with identifica-
tion of the organism on cerebral spinal fluid (CSF) cytology and description of the 
clinical and MRI features, and outcome.
K E Y W O R D S
chorioretinitis, cryptococcosis, fluconazole, France, MRI
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
97
11
 
| 
do
wn
lo
ad
ed
: 
16
.3
.2
02
0
2350 |   BARBRY et Al.
2 |  INVESTIGATIONS
2.1 | Complementary examinations
Dark‐ and light‐adapted electroretinogram (ERG) was per-
formed under general anesthesia. The animal was sedated with 
intravenous propofol 4 mg/kg (PropoVet Multidose, Zoetis) 
and ketamine 3 mg/kg (Anesketin 100 mg/mL, Dechra), and 
then, an isoflurane relay was done. Pupils were dilated with 
topical tropicamide 1%. The electric response of the retinas 
to light stimulation in photopic and scotopic environment as 
well as after a period of adaptation during the ERG was ab-
sent. ERG confirmed alteration of retinal function.
Twenty‐four hours after ERG, the animal started to show 
central nervous system (CNS) involvement, with symmetri-
cal ataxia and impaired postural responses in all four limbs, 
and a generalized seizure. The seizure was managed with di-
azepam (Diazepam, TVM) 1 mg/kg/h. These findings indi-
cated a concurrent central disease.
Complete blood count and biochemical analysis (ie, urea, 
creatinine, ALP, ALT, glycemia, total protein, albumin, glob-
ulin) showed no abnormalities.
Magnetic resonance imaging (MRI) was performed under 
general anesthesia; the animal was sedated with intravenous 
butorphanol 0.3  mg/kg (Torbugesic Vet, Zoetis), midaz-
olam 0.2  mg/kg (Midazolam, Mylan), and propofol 4  mg/
kg (PropoVet Multidose, Zoetis); and then, an isoflurane 
relay was done. The MRI of the brain showed a broad‐based 
extra‐axial plaque‐like lesion in the right olfactory bulb that 
extended mildly to left, as well as along the rostral aspect of 
the falx cerebri, and caudally to the optic chiasm, and within 
the orbital fissure (damage to the emergence of cranial nerves 
III, IV, and VI and of the ophthalmic branch of the V). The 
mass was moderately hyperintense in T2w images, isointense 
in T1w and SST1w precontrast images, and strongly contrast 
enhancing in T1w and SST1w postcontrast images with well‐
defined margins (Figure 2). Diffuse mild irregular thicken-
ing and strong contrast enhancement of the meninges were 
noted in T1w postcontrast images, extending across the brain 
(Figure 3).
Following MRI, a CSF sample was obtained from the 
cerebellomedullary cistern. The fluid was characterized by 
hyperproteinorachie at 1.2 g/L (reference limit < 0.2 g/L) and 
the presence of an abundant population of inflammatory cells 
dominated by clearly activated macrophages (46%) and lobed 
polymorphonuclear neutrophils (44%). No blood contamina-
tion was noted (0 red blood cells; reference limit, <30 red 
blood cells/mL; Figure 4).
Cerebral spinal fluid cytology allowed the direct obser-
vation of eosinophilic spherical elements of variable size 
surrounded by a thick refractive cell wall that sometimes ex-
hibited budding evaginations. These elements, both free and 
intracellular (macrophages), were most likely consistent with 
cryptococci (Figure 5).
Assaying for Cryptococcus neoformans capsular antigens 
in serum by a latex agglutination testing (VEBIO veterinary 
biology) was positive at a dilution of 1/100.
3 |  DIFFERENTIAL DIAGNOSIS
The differential diagnoses for this bilateral chorioretinitis as-
sociated with an extra‐axial mass and diffuse meningitis were 
most likely a fungal disease (aspergillosis, cryptococcosis), 
or a neoplastic process (round cell tumors, such as lymphoma 
or histiocytic sarcoma, or less likely metastatic), another in-
fectious disease (toxoplasmosis, neosporosis), or much less 
likely an immune‐mediated disease.
4 |  TREATMENT
The dog was hospitalized for 15 days. During the first four 
days, the dog was nonambulatory. Treatment with flucona-
zole (Triflucan 200 mg, Pfizer) per os, at a dosage of 5 mg/
kg/BID, was established. Fluid therapy with Ringer's lac-
tate at 2 ml/kg/h was also provided. The dog recovered its 
appetite after two days of hospitalization and was again 
ambulatory after four days. After four days of hospitali-
zation, prednisolone treatment (Dermipred, Ceva Santé 
Animale) was initiated at 1 mg/kg/SID. On the sixth day 
of hospitalization, a complete blood count and biochemis-
try analysis (APL, ALT, total protein and albumin levels) 
revealed no abnormalities. The dog was discharged from 
F I G U R E  1  Fundic examination 
with indirect binocular ophthalmoscopy 
(Heine Omega 500, Herrsching; Volk 
2.2, Panretinal lens, Mentor) revealing an 
ill‐defined papilledema, vast subretinal 
granulomas associated with detachment of 
the retina, as well as numerous small retinal 
hemorrhages OU
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the hospital after 15 days of treatment, blind and slightly 
ataxic but in good general condition. Systemic corticoster-
oids were gradually discontinued (1 mg/kg/SID for 7 days, 
then 0.5  mg/kg/SID for seven days, and then 0.5  mg/kg 
every two days for 7 days), and only fluconazole (Triflucan 
200  mg, Pfizer) was continued at home at the dosage of 
5 mg/kg/BID.
5 |  OUTCOME AND FOLLOW‐UP
A complete clinical and ophthalmological examination as 
well as the liver enzyme levels (ALP and ALT) was per-
formed each month and did not reveal any abnormalities. 
After six months of treatment with fluconazole (Triflucan 
200  mg, Pfizer) at the same dose and frequency, the dog 
was alert and had no neurological signs. Cotton ball test and 
menace response were absent OU. Direct and indirect pupil-
lary light reflexes were present, slowed down, and incom-
plete OU. Indirect ophthalmoscopic examination revealed a 
decrease of the retinal hemorrhages and persistence of the 
subretinal granulomas and several small, pigmented nodules 
scattered throughout the tapetal fundus OU.
6 |  DISCUSSION
Cryptococcosis is a systemic fungal infection of global im-
portance occurring in humans as well as in a large variety 
of animal species including dogs.1 It is mainly due to two 
species of encapsulated yeasts, ranging from 3.5 to 7  µm 
in size, that are soil saprophytes: Cryptococcus neofor-
mans (C  neoformans) and Cryptococcus gattii (C  gattii).2 
Geographically, it is found particularly in North America 
F I G U R E  2  Dorsal pre‐ (A) and 
postcontrast (B) magnetic resonance images 
of the brain showing a well‐defined plaque‐
like lesion (arrow) in the right olfactory 
bulb that extended to the left and along 
the falx cerebri, which was isointense in 
SST1w precontrast sequences, and strongly 
enhancing in SST1w postcontrast sequence
F I G U R E  3  Transverse T1w pre‐ (A) 
and postcontrast (B) image of the forebrain 
showing a thin and strong meningeal 
enhancement encephala (arrows)
F I G U R E  4  Photomicrograph of a cytospin preparation of the 
cerebrospinal fluid, revealing a marked inflammatory pleocytosis 
(macrophages, neutrophils, and eosinophils)
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(Southern California,3 Western British Columbia 4), and on 
the east coast of Australia,5 while it has remained sporadic to 
date in Europe.6,7 The incidence of cryptococcosis is lower 
in dogs than in cats, with a retrospective study indicating a 
risk of infection of <13 out of 100 000.8 It particularly af-
fects dogs under 6 years old, and no gender‐based predisposi-
tion has been reported.9 American Cocker Spaniels,10 Great 
Danes,11 Doberman Pinschers, and German Shepherds 5 ap-
pear to be overrepresented.
Cryptococcosis most often occurs by inhalation of fungal 
yeasts in suspension in the air that then lodge in the nasal, 
paranasal, and pulmonary tissues before spreading more 
widely by blood or direct extension.12 The polysaccharide 
capsule that covers these yeasts, which is useful for the diag-
nosis, protects them from the immune system of the host.13 
Although dissemination can affect any organ, the central 
nervous system (CNS), the eyes, and the skin are most com-
monly affected.14 In our case, invasion of the right olfactory 
bulb, visualized on the MRI, suggests a direct contamination 
across the cribriform plate.10 The eyes are affected in approx-
imately 20 to 40% of dogs affected with cryptococcosis.14 
The most commonly observed ocular abnormalities are mul-
tifocal granulomatous lesions of the choroid that can produce 
a subretinal exudate with secondary retinal detachment,15 
retinal hemorrhages, optic neuritis from progression of the 
chorioretinitis to the optic nerve 16 or from progression of the 
meningitis to the optic nerve,14 and more rarely a retrobulbar 
abscess with destruction of peripheral tissues.1
Definitive diagnosis of systemic cryptococcosis is based 
on direct observation of the microorganisms and/or a posi-
tive fungal culture, and/or a significantly positive latex cryp-
tococcal antigen agglutination testing.4 Two of these three 
methods were used to confirm our diagnostic hypothesis. The 
microorganisms can be visualized in 90% of CSF samples 
when there are neurological manifestations.17 When they are 
not identified, a fungal culture can be performed starting with 
the infected tissues, CSF, or blood, on Sabouraud dextrose 
agar with a growth delay of two to 10 days.4 The latex cryp-
tococcal antigen agglutination testing (LCAT) measures the 
capsular cryptococcal polysaccharide antigen with both high 
specificity and sensitivity18 for the diagnosis of Cryptococcus 
infection. Very recently, a point‐of‐care cryptococcal antigen 
lateral flow assay (LFA) was used to diagnose cryptococ-
cosis in dogs, and the test is suitable for excluding clinical 
cryptococcosis, but confirmatory testing of positive results 
using the LCAT is recommended.19 The neurological symp-
toms led us to investigate yeasts in the CSF, but it would have 
been wise to perform an intravitreal puncture to confirm the 
cryptococcal nature of the chorioretinitis,15 as the microor-
ganisms are found there in 75% of cases when there is ocular 
involvement.14 A PCR‐based test has been used in humans,20 
but its use has not been reported in dogs. Identification of the 
infecting species was not performed in this case, although it 
would have been of epidemiological relevance.
The usefulness of brain imaging in the diagnosis of CNS 
cryptococcosis remains limited. Indeed, in humans, the MRI is 
normal in 50% of cases.21 The lesions are nonspecific and are 
mainly represented by the formation of parenchymal masses, 
isolated or diffuse lesions of the meninges. The MRI lesions ob-
served in our case are similar to those described in the literature 
for dogs.3,6,22 Ocular involvement often occurs with neurological 
involvement in dogs. In case of suspicion of cryptococcosis in-
fection after the ophthalmological examination, the authors ad-
vise to perform a serum latex agglutination test in first intention. 
If the latter is positive, an MRI examination of the brain is then 
recommended, as CNS lesions can be present before the onset of 
neurological signs. As cryptococcosis can also involve the spinal 
cord, MRI should not be limited to the brain, if the neurological 
signs are indicative of a spinal cord lesion.7,23
Cryptococcosis remains hard to treat in dogs and cats, with 
the treatment consisting of the use of systemic antifungals that 
can be used as monotherapy or in combination. There is, how-
ever, not a clearly established protocol. Among the most often 
used antifungals are amphotericin B, flucytosine, fluconazole, 
and itraconazole. Fluconazole has proven to be effective for 
treating cryptococcosis in humans and animals,22 inhibiting 
the synthesis of ergosterol, the main sterol of the fungal cel-
lular membrane. Thus, it is a fungistatic, although it also ex-
hibits fungicidal properties for cryptococcosis, and its good 
penetration across the blood‐brain barrier makes it a treatment 
of choice in case of CNS involvement.14 As azoles have hepa-
totoxic properties, it is recommended to monitor liver param-
eters during the treatment.4 However, fluconazole was used at 
a dose of 5 mg/kg/BID4 in a recent clinical case during 5 years 
without impairment of liver function.23 In the beginning, the 
antifungal treatment needs to be monitored closely (hence 
the merit of hospitalization), as the death of fungal cells can 
F I G U R E  5  Photomicrograph of a cytospin preparation of 
the cerebrospinal fluid showing several yeast forms consistent with 
Cryptococcus species (arrows)
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increase the inflammatory response at the level of the eyes 
and the CNS.15 Although rare in Europe, this clinical case 
brings out the importance of an etiological diagnosis prior to 
implementation of a symptomatic treatment of chorioretinitis. 
Indeed, the use of a treatment based on glucocorticoids prior 
to implementation of an antifungal treatment, as is was the 
case for our animal, can substantially exacerbate progression 
of the disease.5 Prednisone at 1 mg/kg/SID can be added to 
the therapeutic regime after implementation of the antifungal 
treatment in case of intraocular inflammation.15
Despite establishment of a suitable antifungal treatment, 
the prognosis remains poor. In a study of dogs with CNS 
involvement, the median survival time after diagnosis was 
12 days in those receiving antifungal treatment. This median 
increased to 190 days for dogs who survived at least four days 
after the diagnosis.3 In this case, the dog was still alive after 
270 days of treatment. Resolution of the clinical signs does 
not imply the eradication of the infection, as improvement 
occurs well before all of the viable cryptococci have been 
eliminated from the tissues of the host.5 A relapse can occur 
months if not even years after an apparent clinical “cure,” 
and this is so even when the antifungal treatment is contin-
ued.23 Antigen titers should ideally be monitored every two 
or three months when the animal is receiving antifungal treat-
ment, and for at least a year after treatment is stopped.8 In 
this case, for financial reasons, the antigen titer had still not 
been reevaluated since the beginning of the treatment. Lastly, 
in humans the prognosis is directly reevaluated by the delay 
between the onset of clinical signs and the diagnosis.24
7 |  TAKE HOME MESSAGES
Even though cryptococcosis is currently sporadic in Europe6 
and particularly in France, it needs to be part of the differen-
tial diagnostic in cases of bilateral chorioretinitis, particularly 
when it is granulomatous.
The definitive diagnosis of cryptococcosis is based on di-
rect observation of the microorganisms, on a positive fungal 
culture, and/or on a positive latex agglutination test.
The etiological diagnosis with chorioretinitis is important 
as the use of certain symptomatic treatments such as gluco-
corticoids can accelerate progression of the underlying dis-
ease process, in case of infection.
The prognosis for cryptococcosis is poor and directly cor-
relates with the extent and the magnitude of the disease at the 
time of the diagnosis. Implementation of an adequate treat-
ment and rigorous monitoring can, however, quite substan-
tially increase the chances of survival.
CONFLICT OF INTEREST
None declared.
AUTHOR CONTRIBUTIONS
JBB: involved in main work and manuscript writing. ASP: 
involved in manuscript revision. EG: served as ECVDI 
specialist and read and interpreted the MRI results. AD: 
served as ECVDI specialist and revised the manuscript. 
OB: served as Ophthalmology DESV specialist, is in 
charge of the patient, and approved the final version for 
submission.
ORCID
Jean‐Baptiste Barbry   https://orcid.
org/0000-0003-3565-4365 
Anne Sophie Poinsard   https://orcid.
org/0000-0002-8933-4458 
Olivier Balland   https://orcid.org/0000-0003-1672-9018 
REFERENCES
 1. Jacobs GJ, Medleau L. Cryptococcosis. In: Greene CE, ed. 
Infectious diseases of the dog and cat. Philadelphia: WB Saunders 
Co; 1998:383‐390.
 2. Malik R, Krockenberger M, O’Brien C, et al. Cryptococcosis. In: 
Green CE, ed. Infectious diseases of the dog and cat, 3rd edn. St. 
Louis: Elsevier Saunders. 2006:584‐598.
 3. Sykes JE, Sturges BK, Cannon MS, et al. Clinical signs, imaging 
features, neuropathology, and outcome in cats and dogs with cen-
tral nervous system cryptococcosis from California. J Vet Intern 
Med. 2010;24(6):1427‐1438.
 4. Vorathavorn VI, Sykes JE, Feldman DG. Cryptococcosis as an 
emerging systemic mycosis in dogs. J Vet Emerg Crit Care. 
2013;23(5):489‐497.
 5. O’Brien CR, Krockenberger MB, Wigney DI, et al. Retrospective 
study of feline and canine cryptococcosis in Australia from 1981 to 
2001: 195 cases. Med Mycol. 2004;42(5):449‐460.
 6. Robson K, Smith PM. Cryptococcal meningoencephalitis in a dog. 
Veterinary Record. 2011;168(20):538.
 7. Belluco S, Thibaud JL, Guillot J, et al. Spinal cryptococcoma in an 
immunocompetent cat. J Comp Pathol. 2008;139(4):246‐251.
 8. Berthelin CF, Bailey CS, Kass PH, et al. Cryptococcosis of the 
nervous system in dogs. Part 1: epidemiologic, clinical and neuro-
pathologic features. Prog Vet Neurol. 1994;5:88‐97.
 9. Lester SJ, Malik R, Bartlett KH, et al. Cryptococcosis: up-
date and emergence of Cryptococcus gattii. Vet Clin Pathol. 
2011;40(1):4‐17.
 10. Trivedi SR, Sykes JE, Cannon MS, et al. Clinical features and ep-
idemiology of cryptococcosis in cats and dogs in California: 93 
cases (1988–2010). J Am Vet Med Assoc. 2011;239(3):357‐369.
 11. Malik R, Dill‐Macky E, Martin P, et al. Cryptococcosis in dogs: 
a retrospective study of 20 consecutive cases. J Med Vet Mycol. 
1995;33(5):291‐297.
 12. Neilson JB, Fromtling RA, Bulmer GS. Cryptococcus neoformans: 
size range of infectious particles from aerosolized soil. Infect 
Immun. 1977;17(3):634‐638.
 13. Buchanan KL, Murphy JW. What makes Cryptococcus neofor-
mans a pathogen? Emerg Infect Dis. 1998;4(1):71‐83.
2354 |   BARBRY et Al.
 14. Taboada J, Grooters AM. Cryptococcosis. In Ettinger SJ, Feldman 
EC, eds. Textbook of Veterinary Internal Medicine, 7th edn. St. 
Louis, MO: Saunders Elsevier; 2010:988‐992.
 15. Krohne SG. Canine systemic fungal infections. Vet Clin North Am 
Small Anim Pract. 2000;30(5):1063‐1090.
 16. Martin CL. Ocular manifestations of systemic disease. In: Gelatt 
KN, ed. Veterinary Ophthalmology, 3rd edn. Baltimore, MD: 
Lippincott Williams & Wilkins; 1999:1401‐1448.
 17. Berthelin CF, Legendre AM, Bailey CS, et al. Cryptococcosis of 
the nervous system in dogs. Part 2: diagnosis, treatment, monitor-
ing, and prognosis. Prog Vet Neurol. 1994;5:136‐146.
 18. Malik R, McPetrie R, Wigney DI, et al. A latex cryptococcal anti-
gen agglutination test for diagnosis and monitoring of chemother-
apy. Aust Vet J. 1996;74(5):358‐364.
 19. Krockenberger MB, Marschner C, Martin P, et al. Comparing 
immunochromatography with latex antigen agglutination testing 
for the diagnosis of cryptococcosis in cats, dogs and koalas. Med 
Mycol. 2019;1‐8.
 20. Rappelli P, Are R, Casu G, et al. Development of a nested PCR 
for detection of Cryptococcus neoformans in cerebrospinal fluid. 
J Clin Microbiol. 1998;36(11):3438‐3440.
 21. Bretaudeau K, Eloy O, Richer A, et al. Cryptococcal meningo‐en-
cephalitis in an apparently immunocompetent patient. Rev Neurol 
(Paris). 2006;162(2):233‐237.
 22. Tiches D, Vite CH, Dayrell‐Hart B, et al. A case of canine central 
nervous system cryptococcosis: management with fluconazole. 
J Am Anim Hosp Assoc. 1998;34(2):145‐151.
 23. Galban E, Perkins J. Arachnoid diverticulum diagnosis following 
treatment of cryptococcal meningitis in a dog. Clin Case Rep. 
2018;6(4):557‐563.
 24. Aye C, Henderson A, Yu H, Norton R. Cryptococcosis ‐ the impact 
of delay to diagnosis. Clin Microbiol Infect. 2016;22(7):632‐635.
How to cite this article: Barbry J‐B, Poinsard AS, 
Gomes E, Durand A, Balland O. Cryptococcosis with 
ocular and central nervous system involvement in a  
3‐year‐old dog. Clin Case Rep. 2019;7:2349–2354.  
https ://doi.org/10.1002/ccr3.2491
